PSEUDOVITELLIFORM MACULOPATHY SECONDARY TO BRAF AND MEK INHIBITORS IN A PATIENT WITH METASTASIC MELANOMA

被引：0
|
作者：
Alba-Linero, C. [1 ]
Rocha De Lossada, C. [1 ]
Delgado-Fernandez, A. S. [1 ]
Jodar-Marquez, M. [1 ]
Calvo De Mora, M. Rodriguez [1 ]
Berciano-Guerrero, M. A. [2 ]
机构：
[1] Hosp Reg Malaga, Plaza Hosp Civil, Ophthalmol Dept, Malaga 29009, Spain
[2] Hosp Reg Malaga, Oncol Dept, Malaga, Spain
来源：
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS | 2019年 / 33卷 / 05期
关键词：
neuroepithelial detachment; metastasic melanoma; BRAF inhibitors; MEK inhibitors; pseudovitelliform;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1497 / 1500
页数：4
相关论文
共 50 条
  • [31] The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma
    Poizeau, Florence
    Balusson, Frederic
    Lemaitre, Florian
    Tron, Camille
    Pracht, Marc
    Russo, David
    Dinulescu, Monica
    Lesimple, Thierry
    Oger, Emmanuel
    Dupuy, Alain
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (04) : 482 - 490
  • [32] Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma
    Oberle, Marion
    Jamme, Philippe
    Mansard, Sandrine
    Machet, Laurent
    Hervieu, Alice
    Kramkimel, Nora
    Greliak, Anna
    Jarrousse, Anne Sophie
    Derangere, Valentin
    Dudoignon, David
    Descarpentries, Clotilde
    Mortier, Laurent
    JCO PRECISION ONCOLOGY, 2022, 6
  • [33] Growth factor-mediated resistance to BRAF/MEK inhibitors in BRAF mutant melanoma
    Lutterbach, Bart
    Ware, Chris
    Davis, Lenora
    Zhang, Qing
    Zawel, Leigh
    Reilly, John
    Pan, Bo-Sheng
    CANCER RESEARCH, 2012, 72
  • [34] BRAF and MEK resistance in melanoma
    Herlyn, Meenhard
    Villanueva, Jessie
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [35] BRAF and MEK inhibition in melanoma
    Dossett, Lesly A.
    Kudchadkar, Ragini R.
    Zager, Jonathan S.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (04) : 559 - 570
  • [36] Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting
    Tetu, Pauline
    Baroudjian, Barouyr
    Lebbe, Celeste
    CURRENT OPINION IN ONCOLOGY, 2020, 32 (02) : 85 - 90
  • [37] Successful treatment of occult pancreatic melanoma using BRAF/MEK inhibitors
    Mizukami, Yukari
    Kanemaru, Hisashi
    Nakamura, Kayo
    Hashigo, Syunpei
    Kajihara, Ikko
    Miyashita, Azusa
    Aoi, Jun
    Fukushima, Satoshi
    Honda, Yumi
    Ihn, Hironobu
    JOURNAL OF DERMATOLOGY, 2020, 47 (04): : E126 - E127
  • [38] Chemotherapy in patients with metaststic melanoma after progression on BRAF/MEK inhibitors
    Samoylenko, I. V.
    Kharkevich, G.
    Demidov, L. V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] EGF/EGFR signaling in priming for resistance to BRAF/MEK inhibitors in melanoma
    Vander Velde, Robert J.
    Shaffer, Sydney M.
    CANCER RESEARCH, 2024, 84 (03)
  • [40] BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma
    Cybulska-Stopa, Bozena
    Rogala, Pawel
    Czarnecka, Anna M.
    Galus, Lukasz
    Dziura, Robert
    Rajczykowski, Marcin
    Kubiatowski, Tomasz
    Wisniewska, Magdalena
    Gega-Czarnota, Adrianna
    Teterycz, Pawel
    Ziobro, Marek
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    MELANOMA RESEARCH, 2020, 30 (05) : 465 - 471
12345